SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

関節リウマチ治療の技術と世界市場

Therapies for Rheumatoid Arthritis: Technologies and Global Markets

商品番号：SMB-83075
出版社BCC Research
出版年月2025年7月
ページ数184
価格タイプシングルユーザライセンス
価格USD 4,650
種別英文調査報告書

Report Highlights

The global market for rheumatoid arthritis therapies was valued at $28.5 billion in 2024 and is estimated to increase from $30.2 billion in 2025 to reach $41.1 billion by 2030, at a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030.

Report Includes

  • 94 data tables and 51 additional tables
  • In-depth analysis of the global markets for rheumatoid arthritis (RA) treatment therapies
  • Analyses of global market trends, with revenue data for 2024, estimates for 2025, forecasts for 2026, and projected CAGRs through 2030
  • Estimates of the market’s current size and revenue prospects, accompanied by a market share analysis based on therapy type, sales channel and region
  • Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors
  • Insights derived from Porter’s Five Forces model, as well as global supply chain analysis
  • Discussion of the key marketed products and products in different stages of clinical development
  • An analysis of patents, and emerging trends and developments in patent activity
  • Overview of sustainability trends and ESG developments, with consumer attitudes, and the ESG scores and practices of leading companies
  • Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
  • Company profiles of major players within the industry, including AbbVie Inc., Pfizer Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Co., Amgen Inc., and F. Hoffmann-La Roche Ltd.

Report Scope

The current report will provide detailed information on therapies for rheumatoid arthritis (RA). This report analyzes the market trends of RA therapies, with the base year for the study set at 2024, estimated for 2025, and forecast between 2026 and 2030, including compound annual growth rate (CAGR) for the forecast period and regional markets. The report will highlight current and future market potential and provide a detailed analysis of the competitive environment as well as regulatory scenarios, drivers, restraints, and opportunities. The report also covers the market shares for key producers.

The market scope in this report is segmented into therapies, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), steroids/corticosteroids, biosimilars, and others. It also covers over-the-counter (OTC)- and prescription-based sales channels.

The report covers significant geographical regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segmentation will offer a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India. For market estimates, data will be provided for 2024 as the base year, with forecasts for 2025 through 2030.

The report aims to:

  • Analyze RA therapy types.
  • Analyze global market size and segmentation.
  • Understand market constraints and drivers.
  • Provide detailed market forecasts for 2030.
  • Assess market shares, competitiveness, and industry structure.
  • Identify potential long-term impacts on the market for RA therapies.

Report Synopsis

Report MetricsDetails
Base year considered2024
Forecast period considered2025-2030
Base year market size$28.5 billion
Market size forecast$41.1 billion
Growth rateCAGR of 6.3% for the forecast period of 2025-2030
Units considered$ Millions
Segments coveredProduct Type, Cancer Type, Region
Regions coveredNorth America, Europe, Asia-Pacific, South America, Rest of the World
Countries coveredU.S., Canada, Mexico, U.K., France, Italy, Germany, Spain, Austria, Denmark, the Netherlands, Poland, Sweden, Switzerland, Turkey, China, India, Japan, Australia, South Korea, Malaysia, New Zealand, Singapore, Thailand, Vietnam, Brazil, Argentina, Colombia, Paraguay, Peru
Key Market Drivers
  • Increasing Biosimilars for RA Treatment
  • Rising Cases of RA
  • Increasing Aging Population
Companies studied
ABBOTTABBVIE INC.
AMGEN INC.BAYER AG
BRISTOL-MYERS SQUIBB CO.F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.GSK PLC.
JOHNSON & JOHNSON SERVICES INC.LILLY
PFIZER INC.SANOFI
SWEDISH ORPHAN BIOVITRUM ABTEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.

Executive Summary

Summary:

The global market for rheumatoid arthritis therapies was valued at $28.5 billion in 2024 and is estimated to increase from $30.2 billion in 2025 to reach $41.1 billion by 2030, at a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030.

The World Health Organization (WHO) has identified RA as a chronic, systemic inflammation that affects joints and causes pain. It can damage surrounding tissues, the heart, lungs, and the nervous system. Symptoms include persistent pain, stiffness, tenderness, warmth, and swelling, which can limit mobility and daily function. Proper management is crucial.

According to Austin, L. et al. (2020), the REMORA (Remote Monitoring of Rheumatoid Arthritis) study has shown a significant correlation between remote monitoring of RA and decreased disease activity. Similarly, according to Arthritis and Rheumatology (2023), electronic patient outcome measures (ePROMs), deployed through mobile applications and web pages, provide a more comprehensive understanding of RA by capturing the dynamic nature of symptoms like pain, joint swelling, and fatigue. ePROMs foster meaningful patient-physician interactions, enhancing understanding and collaboration while boosting patient confidence and satisfaction. They facilitate a deeper exploration of emotional well-being and coping mechanisms.

According to the Arthritis Foundation, approximately 1.5 million individuals in the U.S. are affected by RA. Women are three times more likely to develop RA than men, with onset typically occurring between ages 30 and 60. RA is uncommon in men under 45. RA treatment is significantly improved by integrating smart technologies like smartphones, smartwatches, and wearables. These offer significant avenues for digital self-management, clinical decision-making, sensor-based tracking, and digital behavior change interventions

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Macroeconomic Factor Analysis
Impact of U.S. Tariffs on the Pharmaceutical Industry
Aging Population
Geopolitical Risks, Trade Wars, and Supply Chain Disruptions
Increasing Healthcare Expenditures
Porter’s Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Increasing Biosimilars for RA Treatment
Rising Cases of RA
Increasing Aging Population
Market Restraints
Loss of Patent Exclusivity
Shortage of Rheumatologists
Side Effects of RA Drugs
Market Opportunities
Technological Advances in RA Therapies
Emerging Targeted Therapies
Increasing Inorganic Strategies amongst Manufacturers
Chapter 4 Regulatory Landscape
Overview
The U.S.
Biologics
Biosimilars
Europe
Asia-Pacific
Chapter 5 Emerging Technologies and Pipeline Analysis
Overview
Artificial Intelligence (AI) and Machine Learning (ML)
Stem Cell Therapy
Immunotherapy
Pipeline Analysis
Patent Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Market for RA Therapies by Therapy Type
Key Takeaways
Disease-modifying Anti-rheumatic Drugs (DMARDs)
Targeted Synthetic DMARDs/JAK Inhibitors
Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
Biosimilars
Steroids
Other Drugs
Global RA Therapies by Sales Channel
Key Takeaways
Prescription Drugs
Over-the-Counter (OTC) Drugs
Geographic Breakdown
Global Market for RA Therapies, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa (MEA)
South America
Chapter 7 Competitive Intelligence
Key Takeaways
Market Share Analysis
Company Share Analysis
Chapter 8 Sustainability in the RA Therapies Market: An ESG Perspective
Introduction to ESG
Sustainability in the Market for RA Therapies
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABBOTT
ABBVIE INC.
AMGEN INC.
BAYER AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
PFIZER INC.
SANOFI
SWEDISH ORPHAN BIOVITRUM AB
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.

List of Tables

List of Tables
Summary Table : Global Market for Rheumatoid Arthritis Therapies, by Region, Through 2030
Table 1 : Current Health Expenditure
Table 2 : Porter’s Five Forces Analysis: RA Therapies Market
Table 3 : Biosimilar Medicines for RA Treatment
Table 4 : RA – Level 3 Cause, 2021
Table 5 : Life Expectancy at Birth, by Country/Region, 2023
Table 6 : Rheumatoid Arthritis – Level 3 Cause, 2021
Table 7 : Commercially Available JAK Inhibitors
Table 8 : Recent Strategic Partnerships in the RA Treatment Market
Table 9 : Select Clinical Trials of RA Therapies
Table 10 : Recent Patents Related to RA Therapies, 2025
Table 11 : Global Market for RA Therapies, by Type, Through 2030
Table 12 : Global Market for DMARDs in RA Therapies, by Type, Through 2030
Table 13 : Global Market for Biologics in RA Therapies, by Type, Through 2030
Table 14 : Global Market for DMARDs in RA Therapies, by Region, Through 2030
Table 15 : Global Market for NSAIDs in RA Therapies, by Region, Through 2030
Table 16 : Biosimilars for RA Treatment
Table 17 : Global Market for Biosimilars in RA Therapies, by Region, Through 2030
Table 18 : Global Market for Steroids in RA Therapies, by Region, Through 2030
Table 19 : Global Market for Other Drugs in RA Therapies, by Region, Through 2030
Table 20 : Global Market for RA Therapies, by Sales Channel, Through 2030
Table 21 : Global Market for Prescription Drugs in RA Therapies, by Region, Through 2030
Table 22 : Global Market for OTC Drugs in RA Therapies, by Region, Through 2030
Table 23 : Global Market for RA Therapies, by Region, Through 2030
Table 24 : North American Market for RA Therapies, by Type, Through 2030
Table 25 : North American Market for DMARDs in RA Therapies, by Type, Through 2030
Table 26 : North American Market for Biologics in RA Therapies, by Type, Through 2030
Table 27 : North American Market for RA Therapies, by Sales Channel, Through 2030
Table 28 : North American Market for RA Therapies, by Country, Through 2030
Table 29 : U.S. Market for RA Therapies, by Type, Through 2030
Table 30 : U.S. Market for RA Therapies, by Sales Channel, Through 2030
Table 31 : Canadian Market for RA Therapies, by Type, Through 2030
Table 32 : Canadian Market for RA Therapies, by Sales Channel, Through 2030
Table 33 : Mexican Market for RA Therapies, by Type, Through 2030
Table 34 : Mexican Market for RA Therapies, by Sales Channel, Through 2030
Table 35 : European Market for RA Therapies, by Type, Through 2030
Table 36 : European Market for DMARDs in RA Therapies, by Type, Through 2030
Table 37 : European Market for Biologics in RA Therapies, by Type, Through 2030
Table 38 : European Market for RA Therapies, by Sales Channel, Through 2030
Table 39 : European Market for RA Therapies, by Country, Through 2030
Table 40 : European Market for RA Therapies, by Country, Through 2030
Table 41 : German Market for RA Therapies, by Type, Through 2030
Table 42 : German Market for RA Therapies, by Sales Channel, Through 2030
Table 43 : U.K. Market for RA Therapies, by Type, Through 2030
Table 44 : U.K. Market for RA Therapies, by Sales Channel, Through 2030
Table 45 : French Market for RA Therapies, by Type, through 2030
Table 46 : French Market for RA Therapies, by Sales Channel, Through 2030
Table 47 : Italian Market for RA Therapies, by Type, Through 2030
Table 48 : Italian Market for RA Therapies, by Sales Channel, Through 2030
Table 49 : Spanish Market for RA Therapies, by Type, Through 2030
Table 50 : Spanish Market for RA Therapies, by Sales Channel, Through 2030
Table 51 : Rest of European Market for RA Therapies, by Type, Through 2030
Table 52 : Rest of European Market for RA Therapies, by Sales Channel, Through 2030
Table 53 : Asia-Pacific Market for RA Therapies, by Type, Through 2030
Table 54 : Asia-Pacific Market for DMARDs in RA Therapies, by Type, Through 2030
Table 55 : Asia-Pacific Market for Biologics in RA Therapies, by Type, Through 2030
Table 56 : Asia-Pacific Market for RA Therapies, by Sales Channel, Through 2030
Table 57 : Asia-Pacific Market for RA Therapies, by Country, Through 2030
Table 58 : Chinese Market for RA Therapies, by Type, Through 2030
Table 59 : Chinese Market for RA Therapies, by Sales Channel, Through 2030
Table 60 : Japanese Market for RA Therapies, by Type, Through 2030
Table 61 : Japanese Market for RA Therapies, by Sales Channel, Through 2030
Table 62 : Indian Market for RA Therapies, by Type, Through 2030
Table 63 : Indian Market for RA Therapies, by Sales Channel, Through 2030
Table 64 : South Korean Market for RA Therapies, by Type, Through 2030
Table 65 : South Korean Market for RA Therapies, by Sales Channel, Through 2030
Table 66 : Australian Market for RA Therapies, by Type, Through 2030
Table 67 : Australian Market for RA Therapies, by Sales Channel, Through 2030
Table 68 : Rest of Asia-Pacific Market for RA Therapies, by Type, Through 2030
Table 69 : Rest of Asia-Pacific Market for RA Therapies, by Sales Channel, Through 2030
Table 70 : MEA Market for RA Therapies, by Type, Through 2030
Table 71 : MEA Market for DMARDs in RA Therapies, by Type, Through 2030
Table 72 : MEA Market for Biologics in RA Therapies, by Type, Through 2030
Table 73 : MEA Market for RA Therapies, by Sales Channel, Through 2030
Table 74 : MEA Market for RA Therapies, by Region, Through 2030
Table 75 : Middle East Market for RA Therapies, by Type, Through 2030
Table 76 : Middle East Market for RA Therapies, by Sales Channel, Through 2030
Table 77 : African Market for RA Therapies, by Type, Through 2030
Table 78 : African Market for RA Therapies, by Sales Channel, Through 2030
Table 79 : South American Market for RA Therapies, by Type, Through 2030
Table 80 : South American Market for DMARDs in RA Therapies, by Type, Through 2030
Table 81 : South American Market for Biologics in RA Therapies, by Type, Through 2030
Table 82 : South American Market for RA Therapies, by Sales Channel, Through 2030
Table 83 : South American Market for RA Therapies, by Country, Through 2030
Table 84 : Brazilian Market for RA Therapies, by Type, Through 2030
Table 85 : Brazilian Market for RA Therapies, by Sales Channel, Through 2030
Table 86 : Argentinian Market for RA Therapies, by Type, Through 2030
Table 87 : Argentinian Market for RA Therapies, by Sales Channel, Through 2030
Table 88 : Rest of South American Market for RA Therapies, by Type, Through 2030
Table 89 : Rest of South American Market for RA Therapies, by Sales Channel, Through 2030
Table 90 : Key Focus Areas in ESG Metrics
Table 91 : ESG Rankings for Leading Companies in the RA Therapies Market, 2024*
Table 92 : Abbreviations Used in this Report.
Table 93 : Report Sources
Table 94 : Abbott: Company Snapshot
Table 95 : Abbott: Financial Performance, FY 2023 and 2024
Table 96 : Abbott: Product Portfolio
Table 97 : AbbVie Inc.: Company Snapshot
Table 98 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 99 : AbbVie Inc.: Product Portfolio
Table 100 : Amgen Inc.: Company Snapshot
Table 101 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 102 : Amgen Inc.: Product Portfolio
Table 103 : Amgen Inc.: News/Key Development, 2023
Table 104 : Bayer AG: Company Snapshot
Table 105 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 106 : Bayer AG: Product Portfolio
Table 107 : Bristol-Myers Squibb Co.: Company Snapshot
Table 108 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 109 : Bristol-Myers Squibb Co.: Product Portfolio
Table 110 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 111 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 112 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 113 : Gilead Sciences Inc.: Company Snapshot
Table 114 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 115 : Gilead Sciences Inc.: Product Portfolio
Table 116 : GSK plc.: Company Snapshot
Table 117 : GSK plc.: Financial Performance, FY 2023 and 2024
Table 118 : GSK plc.: Product Portfolio
Table 119 : Johnson & Johnson Services Inc.: Company Snapshot
Table 120 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 121 : Johnson & Johnson Services Inc.: Product Portfolio
Table 122 : Johnson & Johnson Services Inc.: News/Key Developments, 2022−2024
Table 123 : Lilly: Company Snapshot
Table 124 : Lilly: Financial Performance, FY 2023 and 2024
Table 125 : Lilly: Product Portfolio
Table 126 : Lilly: News/Key Development, 2024
Table 127 : Pfizer Inc.: Company Snapshot
Table 128 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 129 : Pfizer Inc.: Product Portfolio
Table 130 : Pfizer Inc.: News/Key Developments, 2022-2025
Table 131 : Sanofi: Company Snapshot
Table 132 : Sanofi: Financial Performance, FY 2023 and 2024
Table 133 : Sanofi: Product Portfolio
Table 134 : Swedish Orphan Biovitrum AB: Company Snapshot
Table 135 : Swedish Orphan Biovitrum AB: Financial Performance, FY 2023 and 2024
Table 136 : Swedish Orphan Biovitrum AB: Product Portfolio
Table 137 : Swedish Orphan Biovitrum AB: News/Key Developments, 2023 and 2024
Table 138 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 139 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 140 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 141 : Viatris Inc.: Company Snapshot
Table 142 : Viatris Inc.: Financial Performance, FY 2023 and 2024
Table 143 : Viatris Inc.: Product Portfolio
Table 144 : Few Emerging Players in the Rheumatoid Arthritis Market

List of Figures

List of Figures
Summary Figure : Global Market Shares of Rheumatoid Arthritis Therapies, by Region, 2024
Figure 1 : Porter’s Five Forces Analysis of the Market for RA Therapies
Figure 2 : Market Dynamics of Rheumatoid Arthritis
Figure 3 : Global Market Shares of RA Therapies, by Type, 2024
Figure 4 : Global Market Shares of DMARDs in RA Therapies, by Type, 2024
Figure 5 : Global Market Shares of Biologics in RA Therapies, by Type, 2024
Figure 6 : Global Market Shares of DMARDs in RA Therapies, by Region, 2024
Figure 7 : Global Market Shares of NSAIDs in RA Therapies, by Region, 2024
Figure 8 : Global Market Shares of Biosimilars in RA Therapies, by Region, 2024
Figure 9 : Global Market Shares of Steroids in RA Therapies, by Region, 2024
Figure 10 : Global Market Shares of Other Drugs in RA Therapies, by Region, 2024
Figure 11 : Global Market Shares of RA Therapies, by Sales Channel, 2024
Figure 12 : Global Market Shares of Prescription Drugs in RA Therapies, by Region, 2024
Figure 13 : Global Market Shares of OTC Drugs in RA Therapies, by Region, 2024
Figure 14 : Global Market Shares of RA Therapies, by Region, 2024
Figure 15 : North American Market Shares of RA Therapies, by Type, 2024
Figure 16 : North American Market Shares of DMARDs in RA Therapies, by Type, 2024
Figure 17 : North American Market Shares of Biologics in RA Therapies, by Type, 2024
Figure 18 : North American Market Shares of RA Therapies, by Sales Channel, 2024
Figure 19 : North American Market Shares of RA Therapies, by Country, 2024
Figure 20 : U.S. Market Shares of RA Therapies, by Type, 2024
Figure 21 : Canadian Market Shares of RA Therapies, by Type, 2024
Figure 22 : Canadian Market Shares of RA Therapies, by Sales Channel, 2024
Figure 23 : Mexican Market Shares of RA Therapies, by Type, 2024
Figure 24 : Mexican Market Shares of RA Therapies, by Sales Channel, 2024
Figure 25 : European Market Shares of RA Therapies, by Type, 2024
Figure 26 : European Market Shares of DMARDs in RA Therapies, by Type, 2024
Figure 27 : European Market Shares of Biologics in RA Therapies, by Type, 2024
Figure 28 : European Market Shares of RA Therapies, by Sales Channel, 2024
Figure 29 : European Market Shares of RA Therapies, by Country, 2024
Figure 30 : European Market Shares of RA Therapies, by Country, 2024
Figure 31 : German Market Shares of RA Therapies, by Type, 2024
Figure 32 : German Market Shares of RA Therapies, by Sales Channel, 2024
Figure 33 : U.K. Market Shares of RA Therapies, by Type, 2024
Figure 34 : U.K. Market Shares of RA Therapies, by Sales Channel, 2024
Figure 35 : French Market Shares of RA Therapies, by Type, 2024
Figure 36 : French Market Shares of RA Therapies, by Sales Channel, 2024
Figure 37 : Italian Market Shares of RA Therapies, by Type, 2024
Figure 38 : Italian Market Shares of RA Therapies, by Sales Channel, 2024
Figure 39 : Spanish Market Shares of RA Therapies, by Type, 2024
Figure 40 : Spanish Market Shares of RA Therapies, by Sales Channel, 2024
Figure 41 : Rest of European Market Shares of RA Therapies, by Type, 2024
Figure 42 : Rest of European Market Shares of RA Therapies, by Sales Channel, 2024
Figure 43 : Asia-Pacific Market Shares of RA Therapies, by Type, 2024
Figure 44 : Asia-Pacific Market Shares of DMARDs in RA Therapies, by Type, 2024
Figure 45 : Asia-Pacific Market Shares of Biologics in RA Therapies, by Type, 2024
Figure 46 : Asia-Pacific Market Shares of RA Therapies, by Sales Channel, 2024
Figure 47 : Asia-Pacific Market Shares of RA Therapies, by Country, 2024
Figure 48 : Chinese Market Shares of RA Therapies, by Type, 2024
Figure 49 : Chinese Market Shares of RA Therapies, by Sales Channel, 2024
Figure 50 : Japanese Market Shares of RA Therapies, by Type, 2024
Figure 51 : Japanese Market Shares of RA Therapies, by Sales Channel, 2024
Figure 52 : Indian Market Shares of RA Therapies, by Type, 2024
Figure 53 : Indian Market Shares of RA Therapies, by Sales Channel, 2024
Figure 54 : South Korean Market Shares of RA Therapies, by Type, 2024
Figure 55 : South Korean Market Shares of RA Therapies, by Sales Channel, 2024
Figure 56 : Australian Market Shares of RA Therapies, by Type, 2024
Figure 57 : Australian Market Shares of RA Therapies, by Sales Channel, 2024
Figure 58 : Rest of Asia-Pacific Market Shares of RA Therapies, by Type, 2024
Figure 59 : Rest of Asia-Pacific Market Shares of RA Therapies, by Sales Channel, 2024
Figure 60 : MEA Market Shares of RA Therapies, by Type, 2024
Figure 61 : MEA Market Shares of DMARDs in RA Therapies, by Type, 2024
Figure 62 : MEA Market Shares of Biologics in RA Therapies, by Type, 2024
Figure 63 : MEA Market Shares of RA Therapies, by Sales Channel, 2024
Figure 64 : MEA Market Shares of RA Therapies, by Region, 2024
Figure 65 : Middle East Market Shares of RA Therapies, by Type, 2024
Figure 66 : Middle East Market Shares of RA Therapies, by Sales Channel, 2024
Figure 67 : African Market Shares of RA Therapies, by Type, 2024
Figure 68 : African Market Shares of RA Therapies, by Sales Channel, 2024
Figure 69 : South American Market Shares of RA Therapies, by Type, 2024
Figure 70 : South American Market Shares of DMARDs in RA Therapies, by Type, 2024
Figure 71 : South American Market Shares of Biologics in RA Therapies, by Type, 2024
Figure 72 : South American Market Shares of RA Therapies, by Sales Channel, 2024
Figure 73 : South American Market Shares of RA Therapies, by Country, 2024
Figure 74 : Brazilian Market Shares of RA Therapies, by Type, 2024
Figure 75 : Brazilian Market Shares of RA Therapies, by Sales Channel, 2024
Figure 76 : Argentinian Market Shares of RA Therapies, by Type, 2024
Figure 77 : Argentinian Market Shares of RA Therapies, by Sales Channel, 2024
Figure 78 : Rest of South American Market Shares of RA Therapies, by Type, 2024
Figure 79 : Rest of South American Market Shares of RA Therapies, by Sales Channel, 2024
Figure 80 : Leading 10 RA Products, by Sales Revenue, 2023-2024
Figure 81 : Shares of the Global Market for RA Therapies, by Company, 2024
Figure 82 : Pillars of ESG
Figure 83 : Advantages of ESG for Companies
Figure 84 : Abbott: Revenue Share, by Business Unit, FY 2024
Figure 85 : Abbott: Revenue Share, by Region/Country, FY 2024
Figure 86 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 87 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
Figure 88 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 89 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 90 : Bayer AG: Revenue Share, by Business Unit, FY 2024
Figure 91 : Bayer AG: Revenue Share, by Country/Region, FY 2024
Figure 92 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 93 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 94 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 95 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 96 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 97 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 98 : GSK plc.: Revenue Share, by Business Unit, FY 2024
Figure 99 : GSK plc.: Revenue Share, by Country/Region, FY 2024
Figure 100 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2024
Figure 101 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2024
Figure 102 : Lilly: Revenue Share, by Business Unit, FY 2024
Figure 103 : Lilly: Revenue Share, by Country/Region, FY 2024
Figure 104 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 105 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 106 : Sanofi: Revenue Share, by Business Unit, FY 2024
Figure 107 : Sanofi: Revenue Share, by Country/Region, FY 2024
Figure 108 : Swedish Orphan Biovitrum AB: Revenue Share, by Business Unit, FY 2024
Figure 109 : Swedish Orphan Biovitrum AB: Revenue Share, by Country/Region, FY 2024
Figure 110 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, 2024
Figure 111 : Viatris Inc.: Revenue Share, by Business Unit, FY 2024
Figure 112 : Viatris Inc.: Revenue Share, by Country/Region, FY 2024

医療・医薬の最新記事8件